ABVC Biopharma Inc (ABVC) is a Healthcare · Biotechnology company listed on NASDAQ. Price $1.17 (+1.74%), Market cap $0.03B, 52-week low–high $0.91 ~ $4.74.
ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601, which is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus, which is in
Financial statements, price targets, institutional (13F) holdings and related news for ABVC Biopharma Inc are updated in real time on BlackAll Trade.
ABVC Biopharma Inc trades at $1.17 (+1.74%). Real-time quotes and charts are available on BlackAll Trade.
ABVC Biopharma Inc has a market cap of about $0.03B.
ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is i